CytoMed Therapeutics Ltd (GDTC) FinancialsGDTCCytoMed Therapeutics Ltd

Evaluating the bottom line, CytoMed Therapeutics Ltd maintains a gross margin of 1.81%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1153.56%, while the net margin is -1140.67%. These profitability ratios, combined with a Return on Equity (ROE) of -57.88%, provide a clear picture of how effectively GDTC converts its operational activities into shareholder value.

In the context of the broader market, GDTC competes directly with industry leaders such as INTS and PASG. With a market capitalization of $10.25M, it holds a significant position in the sector. When comparing efficiency, GDTC's gross margin of 1.81% stands against INTS's N/A and PASG's N/A. Such benchmarking helps identify whether CytoMed Therapeutics Ltd is trading at a premium or discount relative to its financial performance.

CytoMed has shown some improvement in gross margin, reaching 87.51% in Q1 2026, but continues to report negative net income, with losses of -885,226 SGD. The current ratio has also decreased to 2.64, indicating potential liquidity issues.